Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 4 clients • 12 examiners • 11 art units • 0 of 14 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
K&L Gates - Novartis operates in Biotechnology & Pharmaceuticals. It has 34213 career applications. The firm has a resolved allowance rate of 84.55 percent. It averages 3.82 office actions per allowance. There are 11 pending office actions.
The 84.55 percent allowance rate is based on 34213 career applications. The average of 3.82 office actions per allowance indicates the prosecution effort for successful outcomes. The 11 pending office actions show the current state of the firm's biotechnology practice.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (7%) |
| §103 only | 1 (7%) |
| §112 only | 1 (7%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 3 (21%) |
| Multi-statute (no §101) | 7 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BENAVIDES, JENNIFER ANN | 2 | 51.2% | +47.0% |
| REDDIG, PETER J | 2 | 57.9% | +40.2% |
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| SKELDING, ZACHARY S | 1 | 59.7% | +41.2% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| GIBBS, TERRA C | 1 | 63.7% | +10.3% |
| RAHMAN, MASUDUR | 1 | 72.7% | +31.7% |
| BATES, KEENAN ALEXANDER | 1 | 45.5% | +79.5% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | BRISTOL, LYNN ANNE | 132d overdue |
| 16317943 | TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH A KINASE INHIBITOR | LU, CHENG | 38d overdue |
| 18420525 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | REDDIG, PETER J | — |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | STAVROU, CONSTANTINA E | — |
| 18184860 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | SKELDING, ZACHARY S | — |
| 18149520 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPPRESSION BY TUMOR CELLS | GIBBS, TERRA C | — |
| 18009568 | ZBTB32 INHIBITORS AND USES THEREOF | RAHMAN, MASUDUR | — |
| 17602730 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | BATES, KEENAN ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | BRISTOL, LYNN ANNE | 132d overdue |
| 18339565 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL | REDDIG, PETER J | 55d |
| 18672871 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | BENAVIDES, JENNIFER ANN | — |
| 18420525 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | REDDIG, PETER J | — |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | STAVROU, CONSTANTINA E | — |
| 18454457 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | BENAVIDES, JENNIFER ANN | — |
| 18326373 | METHODS FOR TREATING HEMATOLOGIC CANCERS | OUSPENSKI, ILIA I | — |
| 18184860 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | SKELDING, ZACHARY S | — |
| Client (Assignee) | Pending OAs |
|---|---|
| University of Pennsylvania | 7 |
| Novartis | 5 |
| The Medical College of Wisconsin, Inc. | 1 |
| THE GENERAL HOSPITAL CORPORATION | 1 |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1646 | 2 |
| 1644 | 2 |
| 1632 | 1 |
| 1637 | 1 |
| 1635 | 1 |
| 1633 | 1 |
| 1631 | 1 |
| 1643 | 1 |
| 1642 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18672871 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | Novartis AG | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | May 23, 2024 |
| 18420525 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | The Trustees of the University of Pennsylvania | REDDIG, PETER J | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | Novartis AG | STAVROU, CONSTANTINA E | 1632 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18454457 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | Novartis AG | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Aug 23, 2023 |
| 18339565 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL | The Trustees of the University of Pennsylvania | REDDIG, PETER J | 1646 | §103Other | Final Rejection | 55d | Pending | Jun 22, 2023 |
| 18326373 | METHODS FOR TREATING HEMATOLOGIC CANCERS | The Medical College of Wisconsin, Inc. | OUSPENSKI, ILIA I | 1644 | §112Other | Non-Final OA | — | Pending | May 31, 2023 |
| 18184860 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Novartis AG | SKELDING, ZACHARY S | 1644 | §102§112Other | Non-Final OA | — | Pending | Mar 16, 2023 |
| 18162236 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | The Trustees of the University of Pennsylvania | GROOMS, TIFFANY NICOLE | 1637 | §103§112DP | Final Rejection | — | Pending | Jan 31, 2023 |
| 18149520 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPPRESSION BY TUMOR CELLS | The General Hospital Corporation | GIBBS, TERRA C | 1635 | §101 | Non-Final OA | — | Pending | Jan 03, 2023 |
| 18009568 | ZBTB32 INHIBITORS AND USES THEREOF | Novartis AG | RAHMAN, MASUDUR | 1633 | §102§103 | Final Rejection | — | Pending | Dec 09, 2022 |
| 17602730 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | The Trustees of the University of Pennsylvania | BATES, KEENAN ALEXANDER | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 08, 2021 |
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | The Trustees of the University of Pennsylvania | BRISTOL, LYNN ANNE | 1643 | §103§112Other | Non-Final OA | 132d overdue | Pending | Jun 07, 2019 |
| 16317943 | TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH A KINASE INHIBITOR | The Trustees of the University of Pennsylvania | LU, CHENG | 1642 | §103§112 | Non-Final OA | 38d overdue | Pending | Jan 15, 2019 |
| 16093758 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | The Trustees of the University of Pennsylvania | MARTINEZ, TARA L | 1654 | DP | Final Rejection | 16d overdue | Pending | Oct 15, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial